Highest-materiality recent filing
Prothena shareholders re-elect directors, ratify auditor, approve exec comp at 2026 AGM
Shane M. Cooke re-elected with 22,720,769 for, 11,923,467 against, 9,139 abstain.
Prothena Q1 net income $32.7M on $50M milestone; raises cash guidance
Net income of $32.7M ($0.60 diluted EPS) vs net loss of $60.2M ($1.12 loss) in Q1 2025.
Prothena authorizes up to $100M share repurchase plan through Dec 31, 2026
Board authorized repurchase of up to $100M of ordinary shares; plan expires Dec 31, 2026.
Prothena posts Q4 2025 net loss $21.6M; full-year loss $244.1M; 2026 cash burn guide $50-55M
Net loss $21.6M ($0.40 EPS) in Q4 vs $58.0M loss ($1.08 EPS) in Q4 2024; full-year loss $244.1M ($4.53 EPS).
Prothena board member Paula Cobb resigns effective Dec 31, 2025
Paula Cobb notified Prothena of her resignation from the Board, effective December 31, 2025.
Prothena shareholders approve capital reduction to create distributable reserves
37.8M votes for, 46.7K against, 45.9K abstained at extraordinary general meeting on Nov 19, 2025.
Prothena Q3 net loss $36.5M, nine-month loss $222.5M on charges; pipeline advances
Net loss for Q3 2025 was $36.5M ($0.68/sh) vs $59.0M ($1.10/sh) in Q3 2024; nine-month loss $222.5M ($4.13/sh) vs $64.4M ($1.20/sh).
Prothena PRX012 shows amyloid reduction but higher ARIA-E rates; seeks partnership
Phase 1 ASCENT: PRX012 400 mg achieved mean amyloid PET reduction to 27.47 CL at month 12.
Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM
Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.
Prothena Q2 net loss $125.8M; prasinezumab to enter Phase 3 by end 2025
Net loss $125.8M vs income $66.9M last year; includes $32.6M restructuring charge and $44.9M non-cash tax allowance.
CFO Tran Nguyen base $603,792 (50% bonus target); COO Brandon Smith $544,201 (50%); CSO Wagner Zago $518,000 (40%).
Prothena cuts 63% of workforce, expects $16-20M severance costs; two C-suite execs to leave Aug 1
Workforce reduction of ~63% to cut operating costs; substantially complete by Q4 2025.
Roche to advance prasinezumab to Phase III for Parkinson’s; Phase IIb data missed primary endpoint
Partner Roche advancing prasinezumab into Phase III for early-stage Parkinson’s disease.
Phase 3 AFFIRM-AL did not meet primary endpoint of all-cause mortality (HR=0.915, p=0.7680); secondary endpoints also missed.
Prothena shareholders approve 2M share increase to LTIP, re-elect all directors
Shareholders approved an amendment increasing shares under the 2018 LTIP by 2,000,000, effective May 13, 2025.
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
Max materiality 0.90 · Median 0.70 · Most common event other_material